Sarcomatoid is a term pathologists use to describe cancer cells that have changed shape, transforming from their original form into elongated, spindle-shaped cells that resemble sarcoma (a cancer of connective tissue like muscle or bone). It is not a separate type of cancer. Instead, it describes a pattern of transformation that can happen within many different cancers, including those of the kidney, lung, bladder, and the lining of the chest. When a pathology report mentions sarcomatoid features, it signals a more aggressive form of the disease.
How Cancer Cells Become Sarcomatoid
Most cancers start in epithelial cells, the tightly packed cells that line organs and surfaces throughout the body. In their normal state, these cells are orderly, sticking together with adhesion proteins. Sarcomatoid transformation happens when epithelial cancer cells undergo a biological shift called epithelial-to-mesenchymal transition, or EMT. During this process, the cells lose the “glue” that holds them together (a protein called E-cadherin), change from a compact, cube-like shape to a long, fiber-like shape, and gain the ability to move more freely through tissue.
This shift is what makes sarcomatoid tumors more dangerous. Cells that can detach and migrate are better at invading surrounding tissue and spreading to distant organs. Under a microscope, pathologists see high-grade spindle cells that divide rapidly, often with frequent cell division figures visible in the tissue sample. The tumor may show a clear transition zone where the original cancer type morphs into this more aggressive spindle-cell pattern.
Where Sarcomatoid Features Appear
Sarcomatoid change has been documented across a wide range of organ sites. The cancers most commonly associated with it include kidney (renal cell carcinoma), lung, bladder (urothelial carcinoma), head and neck, pancreas, and the pleural lining (mesothelioma). In breast cancer, a similar transformation is often called metaplastic carcinoma. Each organ site uses slightly different terminology, but the underlying biology is the same: epithelial cancer cells taking on sarcoma-like characteristics.
Sarcomatoid Kidney Cancer
In renal cell carcinoma, sarcomatoid features appear in roughly 4% of all cases. That number jumps to about 20% in patients whose cancer has already spread. Any subtype of kidney cancer can develop sarcomatoid change, including clear cell, papillary, and chromophobe variants. Under the international grading system used by pathologists (the ISUP system), the presence of any amount of sarcomatoid tissue automatically classifies the tumor as Grade 4, the highest grade, regardless of what the rest of the tumor looks like. Pathologists also report the sarcomatoid component separately because even a small percentage of it changes the expected course of the disease.
Historically, median survival for sarcomatoid kidney cancer has been 6 to 13 months, and five-year survival for metastatic cases sits between roughly 24% and 33%. Standard treatments like surgery and older systemic therapies have shown limited effectiveness against this variant.
Sarcomatoid Lung Cancer
Pulmonary sarcomatoid carcinoma is a rare subgroup of non-small cell lung cancer. The World Health Organization divides it into five subtypes: pleomorphic carcinoma, spindle-cell carcinoma, giant-cell carcinoma, carcinosarcoma, and pulmonary blastoma. Pleomorphic carcinoma is the most common, making up over half of cases, and accounts for 2 to 3% of all surgically removed lung cancers.
To qualify as pleomorphic, the sarcoma-like spindle or giant cells must make up at least 10% of the tumor tissue. Some tumors consist entirely of these cell types with no recognizable epithelial component remaining. Compared with other forms of non-small cell lung cancer, sarcomatoid lung cancer tends to invade locally and metastasize earlier, even when caught at an early stage. Overall survival is roughly 20%, compared to about 45% for other non-small cell lung cancers. With conventional chemotherapy alone, median survival is less than 7 months.
Sarcomatoid Mesothelioma
Mesothelioma of the pleural lining comes in three histological types: epithelioid, sarcomatoid, and biphasic (a mix of both). Sarcomatoid mesothelioma carries the worst prognosis of the three. With systemic therapy, median survival for advanced-stage mesothelioma is approximately one year, but newer immunotherapy combinations have shown meaningful improvement for the non-epithelioid subtypes, extending median survival from about 8.8 months with chemotherapy to 16.5 months.
Diagnosing sarcomatoid mesothelioma requires careful lab work because spindle-shaped tumor cells can look similar to other conditions. Pathologists rely on a panel of staining markers. Keratin proteins confirm that the cells originated from epithelial tissue despite their sarcoma-like appearance. Additional markers like D2-40 and podoplanin are highly sensitive for confirming the mesothelioma diagnosis. If markers like CD34, desmin, or bcl-2 stain positive, sarcomatoid mesothelioma is essentially ruled out.
How Pathologists Confirm Sarcomatoid Change
Since sarcomatoid cells look like sarcoma under a microscope, the key diagnostic challenge is proving these cells actually originated from an epithelial cancer rather than being a true sarcoma. Pathologists do this through immunohistochemistry, a technique that uses antibodies to detect specific proteins in tumor tissue. Sarcomatoid carcinoma cells typically retain at least some epithelial markers (especially cytokeratins) while also expressing mesenchymal markers like vimentin or smooth muscle proteins. This dual expression, part epithelial and part mesenchymal, is the hallmark that distinguishes sarcomatoid carcinoma from a true sarcoma.
The proportion of sarcomatoid tissue in the overall tumor matters. A tumor that is 5% sarcomatoid behaves differently from one that is 80% sarcomatoid, and pathologists typically estimate this percentage in their reports. For lung cancer, a formal diagnosis of sarcomatoid carcinoma requires a surgically removed specimen rather than a small biopsy, because the spindle-cell component may not be captured in a needle sample.
Why Sarcomatoid Tumors Are More Aggressive
Across every organ site, sarcomatoid transformation correlates with faster growth, higher rates of local recurrence, and earlier distant spread. In a study comparing sarcomatoid carcinoma of the oral cavity with conventional squamous cell carcinoma, patients with sarcomatoid tumors had a mean disease-free survival of 12.4 months, while patients with stage IV conventional squamous cell carcinoma averaged 19.6 months, a significant gap despite the conventional group presenting with worse staging factors. This pattern holds broadly: the sarcomatoid component makes the cancer harder to control regardless of where it originates.
The biological explanation ties back to EMT. Cells that have undergone this transition activate genetic programs associated with invasion and metastasis. Specific transcription factors drive the process, repressing the epithelial identity and promoting the ability to migrate, resist cell death, and evade immune detection.
Treatment Response and Immunotherapy
Sarcomatoid tumors have historically responded poorly to conventional chemotherapy and targeted therapies. This is one reason they carry such grim survival statistics across organ sites. However, immune checkpoint inhibitors have emerged as a more effective option for many sarcomatoid cancers.
In sarcomatoid lung cancer, combining checkpoint inhibitors with chemotherapy has produced response rates around 73 to 74%, with disease control rates near 95% in recent studies. Even checkpoint inhibitors used alone have shown a 54.5% response rate, with a median time before the cancer progresses of 7 months. These numbers represent a substantial improvement over chemotherapy alone. For sarcomatoid mesothelioma, dual immunotherapy nearly doubled median survival compared to chemotherapy (16.5 versus 8.8 months).
Sarcomatoid tumors tend to have high levels of genetic mutations and greater immune cell infiltration, which may explain why they respond better to immunotherapy than to traditional chemotherapy. This is an area where the aggressiveness of the tumor, paradoxically, may create a vulnerability that newer treatments can exploit.